Clinical trials: NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis)
Immune Checkpoint Inhibitor, Chemotherapy Effect
Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma
This prospective pilot study to evaluate the efficacy and safety of the anti-PD-1 antibody combine with Peg-asparaginase and Chidamide regimen for stage IE and IIE ENKTL.
- Conditions
- Immune Checkpoint Inhibitor, Chemotherapy Effect, Epigenetic Disorder, NK/T-cell Lymphoma of Nasal Cavity
- Trial name
- NCT04414969
- Testing
- Anti-PD-1 antibody+Peg-Asparaginase+Chidamide
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Hunan Cancer Hospital
NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis), NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)
Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type
The purpose of this study is to test how well pembrolizumab shrinks Early-Stage NK/T-cell Lymphoma (ENKTL) in participants who have not yet received chemotherapy.
- Trial name
- NCT03728972
- Testing
- Pembrolizumab
- Where
- 10 sites in United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center